Search

everythinglearnresearchcommunity

for

Search:↓

A 26-year-old man shared his positive results after 10 months of treating male pattern baldness using a regimen that includes Estradiol Enanthate, DHPA, Bicalutamide, Dutasteride, oral and topical Minoxidil, and a dermaroller. He experienced mild gynecomastia and reduced body hair as side effects but was satisfied with the outcome.

Minoxidil increases blood supply to the scalp, strengthening dormant follicles and extending the growth phase, but may increase scalp activity that can be countered with DHT blockers. Women experiencing side effects from finasteride or dutasteride for hair loss might consider alternatives like estrogen, especially if on birth control.

, you can find it online with a script This user was discussing their progress with hair loss treatments including 5mg oral Minoxidil and combining 3mg oral Minoxidil with MTF HRT. They also discussed side effects of increased body hair in other parts of the body.

The user experienced significant hair growth using topical finasteride and minoxidil but noticed nipple changes, suggesting early gynecomastia. They plan to stop the treatment and consider blood work to check hormonal balance.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The user switched from topical to oral minoxidil to improve hair regrowth but experienced significant shedding after one month. They are considering continuing oral minoxidil for six months before deciding whether to switch back to topical if no improvements occur.

A user is considering switching from oral to topical treatments for hair loss due to side effects like watery semen and erectile dysfunction. They are currently using oral finasteride and minoxidil and are concerned about potential sexual side effects with topical use.

A trans woman is using finasteride, minoxidil, microneedling, and HRT to address hair loss, with noticeable improvement in hairline shape and presence of vellus hairs. She is considering hair transplants if these treatments don't yield desired results within a year or two.

A 20-year-old female with PCOS is experiencing hair loss and excessive facial hair. She is using ketoconazole and caffeine shampoos, microneedling, and considering anti-androgens like finasteride, but is cautious about minoxidil due to facial hair concerns.

A 24-year-old shared their hair loss journey, switching from a 3-in-1 medication (finasteride, minoxidil, biotin) to a stronger 4-in-1 treatment (finasteride, dutasteride, minoxidil, biotin) with no side effects and noticeable hair growth. The user also discussed using hair dye cautiously to enhance the appearance of vellus hairs.

A 32-year-old male noticed accelerated hair loss after turning 30 and has been using minoxidil and finasteride with breaks, but stopped finasteride due to concerns about side effects. He is considering alternatives like topical treatments, ketoconazole shampoo, and possibly a future hair transplant.

Finasteride and its effects on hair loss, with discussions on the role of estradiol and estrogen. Users debate whether increased estrogen from DHT blockers contributes to hair regrowth, with concerns about potential side effects like chemical castration.

The user is experiencing hair shedding after using minoxidil and is considering switching to dutasteride while planning to increase their oral minoxidil dose. They also use nicotine pouches, Vyvanse, and GHK-Cu, and have noticed thicker eyebrows and lashes from oral minoxidil.

Finasteride can increase estrogen levels, causing dizziness and nausea. Users discuss adjusting treatment and diet, and explore alternatives for hair loss management.

A user on 1mg finasteride for a year has low estradiol levels but no significant symptoms, and others suggest monitoring without immediate concern. Some users discuss potential effects of low estrogen, like low libido, but the user reports no erectile dysfunction.

The user experienced increased shedding and an itchy scalp after switching from Ascend to Aurobindo finasteride. They are considering switching to dutasteride and are concerned about elevated estrogen levels and the effectiveness of adding minoxidil later.

A 30-year-old man is considering quitting Finasteride due to sexual side effects, including reduced libido and difficulty reaching orgasm, despite its effectiveness in treating hair loss. He is exploring other factors like relationship issues and potential low testosterone, and is considering getting blood work done.

A 48-year-old man has been using minoxidil for 15 years and considered finasteride but stopped due to potential side effects. He is concerned about his mental health and the impact of hair loss on self-image, and he encourages support among men experiencing hair loss.

A 26-year-old man who had a hair transplant and used minoxidil with good results is now experiencing shedding and considering finasteride. He's concerned about high progesterone and mild erectile dysfunction before starting the treatment.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

Minoxidil may cause increased prolactin levels, leading to side effects like puffy nipples and chest tenderness. Users experienced these issues and considered stopping minoxidil while continuing or switching to other treatments like finasteride, microneedling, and supplements.

Minoxidil 0.5% MMP® showed better results in parietal-vertex regions for less advanced female pattern hair loss compared to Minoxidil 5%. MMP® with Minoxidil can improve the quality of life for these patients.

The conversation discusses hair loss treatments for a 30-year-old female, comparing red light therapy with minoxidil and finasteride. Concerns about hormonal impact and potential pregnancy are raised, with suggestions to consider spironolactone and microneedling, while emphasizing the importance of consulting a dermatologist.

Female experiencing hair loss for 10 years used 50mg Spironolactone and 5% minoxidil with decent results. Recently had massive shedding, but blood tests were fine and still taking original medications.

A 19-year-old trans female has been using topical minoxidil and dermarolling for nearly two months, alongside oral minoxidil, finasteride, spironolactone, and estrogen. She noticed significant hair improvement after starting topical minoxidil and dermarolling.

A 19-year-old male experienced significant hair loss, initially thought to be male pattern baldness (MPB), and used minoxidil and briefly finasteride. After realizing the issue was telogen effluvium (TE), he improved his diet and supplemented with vitamins, which led to substantial hair regrowth.

The user is considering switching between topical minoxidil (10%) and oral minoxidil (2.5mg) to manage hair shedding around the temples, while also using a dermaroller and biotin. They are concerned about the potential side effects of oral minoxidil, such as hypertrichosis, and the impact on hair shedding if they stop using it.

A person shared their hair regrowth journey using HIMS topical treatments with finasteride, minoxidil, hormone replacement therapy (HRT), and microneedling. They also discussed their transition as a transgender woman and the positive impact of HRT on hair recovery.

Finasteride has no effect on the user's estradiol levels, and body fat may influence aromatization. The user is on testosterone replacement therapy and uses everyday injections to manage high RBC count, with plans to measure DHT, DHEA-S, and pregnenolone levels.